Postprandial effects of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil in type 2 diabetes patients: a randomised controlled trial

被引：0
|
作者：
Sjogren, L.
Olausson, J.
Strindberg, L.
Mobini, R.
Fogelstrand, P.
Hulten, L. Mattsson
Jansson, P. -A.
机构：
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
116
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [1] Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial
    Sjogren, L.
    Olausson, J.
    Strindberg, L.
    Mobini, R.
    Fogelstrand, P.
    Hulten, L. Mattsson
    Jansson, P. -A.
    DIABETIC MEDICINE, 2016, 33 (09) : 1299 - 1301
  • [2] Phosphodiesterase-5 (PDE-5) Inhibitors and Ototoxicity: A Systematic Review
    Manna, Sayan
    Gray, Mingyang Liu
    Kaul, Vivian F.
    Wanna, George
    OTOLOGY & NEUROTOLOGY, 2019, 40 (03) : 276 - 283
  • [3] Phosphodiesterase-5 (PDE-5) Inhibitor, Tadalafil, Activates NO/Sirt1/PGC-1 Signaling And Attenuates Mitochondrial Dysfunction In Type 2 Diabetic Hearts
    Koka, Saisudha
    Aluri, Hema S.
    Lesnefsky, Edward J.
    Kukreja, Rakesh C.
    CIRCULATION, 2012, 126 (21)
  • [4] Udenafil - A New Phosphodiesterase-5 (PDE-5) Inhibitor - in Portal Hypertension: An Open-Label Dose-Finding Trial
    Kreisel, Wolfgang
    Deibert, Peter
    Kupcinskas, Limas
    Sumskiene, Jolanta
    Appenrodt, Beate
    Eggerking, Susanne
    Martin, Rossle
    Zipprich, Alexander
    Mohrbacher, Ralf
    Greinwald, Roland
    Sauerbruch, Tilman
    GASTROENTEROLOGY, 2011, 140 (05) : S598 - S598
  • [5] Cardiovascular localization of phosphodiesterase type 5 (PDE-5)
    Parums, DV
    Charlton, RG
    Ridden, J
    Cindrova, T
    Johnson, N
    Burslem, F
    Phillips, S
    JOURNAL OF PATHOLOGY, 2001, 193 : 38A - 38A
  • [6] Decreased Permeability Surface Area for Glucose in Obese Women with Postprandial Hyperglycemia: No Effect of Phosphodiesterase-5 (PDE-5) Inhibition
    Sandqvist, M.
    Strindberg, L.
    Lonnroth, P.
    Jansson, P. -A.
    HORMONE AND METABOLIC RESEARCH, 2013, 45 (08) : 556 - 560
  • [7] Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
    Arman Shafiee
    Razman Arabzadeh Bahri
    Mohammad Mobin Teymouri Athar
    Fatemeh Afsharrezaei
    Mostafa Gholami
    BMC Gastroenterology, 23
  • [8] Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
    Shafiee, Arman
    Bahri, Razman Arabzadeh
    Teymouri Athar, Mohammad Mobin
    Afsharrezaei, Fatemeh
    Gholami, Mostafa
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [9] Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia
    Cantrell, Matthew A.
    Baye, Jordan
    Vouri, Scott Martin
    PHARMACOTHERAPY, 2013, 33 (06): : 639 - 649
  • [10] The Selective Phosphodiesterase-5 Inhibitor Tadalafil Induces Microvascular and Metabolic Effects in Type 2 Diabetic Postmenopausal Females
    Murdolo, Giuseppe
    Sjostrand, Mikaela
    Strindberg, Lena
    Lonnroth, Peter
    Jansson, Per-Anders
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (01): : 245 - 254
12345